MD · the NYSE · USD · Market cap $2.2B · 4,280 employees
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States.
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Pediatrix Medical Group, Inc. holds its Accumulation at $26.80. The statistical read favours the sellers, held for 48 days.
As held on the ledger · 2026-08-27
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 48 days
Price at the screen
$26.80
Valuation
12.82 trailing · 10.99 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.65
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.25%
Below 33%
Interest-bearing debt is just 28.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.54%
Below 33%
Cash held in interest-bearing accounts and securities is 5.5% of assets, under the one-third limit.
Pass
Receivables
26.92%
Below 49%
Money owed to the company is 26.9% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 4.5% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Hold. The average target sits +4% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Paediatric care provider offers almost no margin
Every day fragile newborns depend on specialist teams inside US hospitals, yet the company delivering that care trades barely below our fair value. With revenue expanding only 4% and a slim 7% gap to our $28 mark, there is little reason to step in when the current price already sits at $26.13. Analysts see the same picture, clustering their targets right around today's level.
The business clears our ethical screen and earns a solid 21% ROE with a forward multiple of 11.1x, but those strengths do not create an opportunity. Low single-digit growth and an unknown moat leave the shares looking fairly valued rather than overlooked. A 9% profit margin offers stability, yet nothing here suggests the market has mispriced the risks.
Currency or regulatory shocks in healthcare could quickly close the tiny gap that exists. We therefore pass. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MD trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
2026-08-05Distribution$26.13+7.5%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
2026-07-18Distribution$24.30+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
2026-07-03Distribution$24.30+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Distribution$24.30Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
